Transgenomic to Present at OneMedForum San Francisco 2015 Conference

OneMedForum 2015

OMAHA, Neb.--()--Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that Chief Executive Officer Paul Kinnon will give a corporate presentation at the 8th Annual OneMedForum Conference being held at the Marriott Marquis Hotel in San Francisco, CA. Transgenomic will present on Tuesday, January 13, 2015 at 11:10 am PT.

Mr. Kinnon will discuss the company’s commercialization strategy for its Multiplexed ICE COLD-PCRTM (MX-ICP) technology. MX-ICP is a transformational high sensitivity DNA amplification technology that makes possible the simultaneous detection of known and unknown mutations in multiple genes from either tumor samples or any liquid sample, such as blood or urine.

For more information about the OneMedForum Conference, visit www.onemedconferences.com.

About Transgenomic

Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCRTM and its unique genetic tests provided through its Patient Testing business. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.

Contacts

Investor Contact:
Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com
or
Media Contact:
BLL Partners LLC
Barbara Lindheim, 212-584-2276
blindheim@bllbiopartners.com

Contacts

Investor Contact:
Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com
or
Media Contact:
BLL Partners LLC
Barbara Lindheim, 212-584-2276
blindheim@bllbiopartners.com